Dyne Therapeutics Inc. (DYN)
16.36
+0.09 (0.55%)
Upcoming Events
Latest Headlines
Top 4 Healthcare Stocks Backed by Raymond James Analysts
October 8, 2026 9:53 AM - StreetInsider
Dyne Therapeutics (DYN) Reiterated at Overweight by Cantor Fitzgerald
October 8, 2026 7:08 AM - StreetInsider
Form 4 Dyne Therapeutics, Inc. For: Oct 02 Filed by: Posner Brian S
October 6, 2026 4:15 PM - SEC Filing
Increasing unusual call option volume: GFL DYN SDGR QSR QSI HBAN ITB BIRK PACB
October 2, 2026 6:16 AM - StreetInsider
Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN)
September 30, 2026 10:00 AM - StreetInsider
Dyne Therapeutics (DYN) PT Lowered to $32 at H.C. Wainwright
September 30, 2026 7:13 AM - StreetInsider
Dyne Therapeutics (DYN) Reiterated at Overweight by Cantor Fitzgerald on Ph1/2 Data Release
September 30, 2026 7:00 AM - StreetInsider
Jefferies Reiterates Buy Rating on Dyne Therapeutics (DYN)
September 30, 2026 5:43 AM - StreetInsider
Dyne Therapeutics stock rises on positive DM1 trial results
September 29, 2026 4:54 PM - StreetInsider
Form 8-K Dyne Therapeutics, Inc. For: Sep 29
September 29, 2026 4:10 PM - SEC Filing
Dyne Therapeutics reports one-year DM1 trial data for z-basivarsen
September 29, 2026 4:05 PM - StreetInsider
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
September 29, 2026 4:05 PM - StreetInsider
Piper Sandler Reiterates Overweight Rating on Dyne Therapeutics (DYN)
September 29, 2026 9:25 AM - StreetInsider
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 17, 2026 4:05 PM - StreetInsider
Dyne Therapeutics (DYN) PT Lowered to $36 at Morgan Stanley
September 9, 2026 7:54 AM - StreetInsider
Dyne Therapeutics (DYN) PT Lowered to $30 at RBC Capital Following NVS Setback
September 9, 2026 7:23 AM - StreetInsider
Dyne Therapeutics (DYN) PT Lowered to $26 at Baird
September 9, 2026 6:40 AM - StreetInsider
Increasing unusual option volume: DYN GPRO KC DK ATAI PS FISV DPRO UGA TTAN REI CHPT BRZE
September 9, 2026 5:34 AM - StreetInsider
JPMorgan Downgrades Dyne Therapeutics (DYN) to Underweight
September 8, 2026 4:26 PM - StreetInsider
Dyne Therapeutics (DYN) PT Lowered to $37 at Raymond James
September 8, 2026 10:39 AM - StreetInsider
Stifel on Dyne Therapeutics Inc. (DYN): 'we'd be buyers on weakness'
September 8, 2026 5:38 AM - StreetInsider
Dyne Therapeutics to present DMD preclinical data at NMSG meeting
September 3, 2026 7:30 AM - StreetInsider
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
September 3, 2026 7:30 AM - StreetInsider
Dyne Therapeutics to Participate in Upcoming Investor Conferences
September 2, 2026 7:30 AM - StreetInsider
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 20, 2026 4:05 PM - StreetInsider
Form 4 Dyne Therapeutics, Inc. For: Aug 13 Filed by: Rhodes Jason P
August 17, 2026 5:30 PM - SEC Filing
Form 4 Dyne Therapeutics, Inc. For: Aug 13 Filed by: Friedl-Naderer Johanna
August 17, 2026 4:09 PM - SEC Filing
Form 4 Dyne Therapeutics, Inc. For: Aug 13 Filed by: Kerr Douglas
August 17, 2026 4:08 PM - SEC Filing
Form 4 Dyne Therapeutics, Inc. For: Aug 13 Filed by: Cox John
August 17, 2026 4:07 PM - SEC Filing
Form 4 Dyne Therapeutics, Inc. For: Aug 13 Filed by: Lucera Erick
August 17, 2026 4:06 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Dyne Therapeutics (DYN)
August 17, 2026 6:42 AM - StreetInsider
Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
August 14, 2026 5:48 PM - SEC Filing
Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
August 14, 2026 5:48 PM - SEC Filing
Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.
August 14, 2026 5:47 PM - SEC Filing
Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.
August 13, 2026 5:37 PM - SEC Filing
Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
August 13, 2026 5:36 PM - SEC Filing
Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
August 13, 2026 5:36 PM - SEC Filing
Form 144 Dyne Therapeutics, Inc. Filed by: Cox John
August 13, 2026 5:04 PM - SEC Filing
Form 144 Dyne Therapeutics, Inc. Filed by: Lucera Erick
August 13, 2026 5:04 PM - SEC Filing
Form 144 Dyne Therapeutics, Inc. Filed by: Kerr Douglas
August 13, 2026 5:03 PM - SEC Filing
Form SCHEDULE 13G/A Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
August 13, 2026 4:52 PM - SEC Filing
Form SCHEDULE 13G/A Dyne Therapeutics, Inc. Filed by: Janus Henderson Group Ltd.
August 13, 2026 12:47 PM - SEC Filing
Form SCHEDULE 13G/A Dyne Therapeutics, Inc. Filed by: FMR LLC
August 6, 2026 10:21 AM - SEC Filing
Dyne Therapeutics (DYN) PT Lowered to $45 at Morgan Stanley
July 31, 2026 8:00 AM - StreetInsider
Dyne Therapeutics (DYN) PT Raised to $35 at RBC Capital
July 30, 2026 8:33 AM - StreetInsider
Dynegy (DYN) Misses Q2 EPS by 33c
July 29, 2026 5:49 PM - StreetInsider
Form 8-K Dyne Therapeutics, Inc. For: Jul 29
July 29, 2026 4:35 PM - SEC Filing
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
July 29, 2026 4:30 PM - StreetInsider
Form 4 Dyne Therapeutics, Inc. For: Jul 27 Filed by: Kersten Dirk
July 29, 2026 4:15 PM - SEC Filing
Form 10-Q Dyne Therapeutics, Inc. For: Jun 30
July 29, 2026 4:06 PM - SEC Filing
Form SCHEDULE 13G/A Dyne Therapeutics, Inc. Filed by: BlackRock, Inc.
July 28, 2026 4:45 PM - SEC Filing
FDA clears Dyne Therapeutics IND for DYNE-302 in rare muscle disease
July 28, 2026 7:32 AM - StreetInsider
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
July 28, 2026 7:30 AM - StreetInsider
Form 144 Dyne Therapeutics, Inc. Filed by: ForDyne B.V.
July 27, 2026 4:20 PM - SEC Filing
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 24, 2026 4:05 PM - StreetInsider
Dyne Therapeutics closes $431.4M public stock offering
July 23, 2026 4:05 PM - StreetInsider
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
July 23, 2026 4:05 PM - StreetInsider
Cantor Fitzgerald Starts Dyne Therapeutics (DYN) at Overweight
July 23, 2026 6:24 AM - StreetInsider
Full Article List
